Abstract:The last decade saw impressive advances not only in the discovery of gene mutations causing epilepsy, but also in unraveling the molecular mechanisms underlying the clinical manifestations of the disease. Increasing evidence is emerging that understanding these mechanisms is relevant for selection of the most appropriate treatment in the affected individual(s). The present article discusses the therapeutic implications of epilepsy-causing variants affecting a broad range of targets, from ion channels to genes controlling cellular metabolism and cell signaling pathways. Identification of a precise genetic etiology can direct physicians to (i) prescribe treatments that correct specific metabolic defects (e.g., the ketogenic diet for GLUT1 deficiency, or pyridoxine for pyridoxine-dependent epilepsies); (ii) avoid antiepileptic drugs (AEDs) that can aggravate the pathogenic defect (e.g., sodium channel blocking drugs in SCN1A-related Dravet syndrome), or (iii) select AEDs that counteract the functional disturbance caused by the gene mutation (e.g., sodium channel blockers for epilepsies due to gain-of-function SCN8A mutations). In some instances, different pathogenic variants of the same gene can have opposite functional effects, which determines whether certain treatments can be beneficial or deleterious (e.g., gain-of-function versus loss-of-function variants in SCN2A determine whether sodium channel blockers improve or worsen seizure control). There are also cases where functional disturbances caused by the gene defect may not be corrected by existing AEDs, but can be countered by medications already available in the market for other indications (e.g., memantine has been used to treat the epileptic encephalopathy caused by a specific gain-of-function GRIN2A mutation), thus making 'drug repurposing' a valuable tool for personalized epilepsy therapies. As our understanding of pathogenic mechanisms improve, opportunities arise for development of treatments targeting the specific gene defect or its consequences. Everolimus, an mTOR inhibitor approved for the treatment of focal seizures associated with tuberous sclerosis complex, is an example of a medication targeting the etiological mechanisms of the disease. Several treatments aimed at correcting specific pathogenic defects responsible for rare genetic epilepsies are currently in development, and range from traditional small molecules to novel approaches involving peptides, antisense oligonucleotides, and gene therapy.

Individualized Medicine for Epilepsy -Based on Genetic Information-

Identifying mutations in epilepsy genes: Impact on treatment selection

Genetic Background of Epilepsy and Antiepileptic Treatments

The pharmacogenomics of epilepsy

The Current Precision Medicine Approaches in Genetic Epilepsies

Advances in the individualized treatment of novel antiepileptic drugs for children

Genetic Literacy Series: Clinical Application Of Pharmacogenetics For Adverse Reactions To Antiepileptic Drugs An Ilae Commission Review

Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications

Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis

The evolution of antiseizure medication therapy selection in adults: Is artificial intelligence -assisted antiseizure medication selection ready for prime time?

A Systems Biology Approach for Personalized Medicine in Refractory Epilepsy

Genetic Literacy Series: Clinical Application of Pharmacogenetics for Adverse Reactions to Antiepileptic Drugs

A systems-level framework for anti-epilepsy drug discovery

Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for Epilepsy

New advances in pharmacoresistant epilepsy towards precise management-from prognosis to treatments

Pharmacoresponse in Genetic Generalized Epilepsy: a Genome-Wide Association Study

Genetic Predictors of the Maximum Doses Patients Receive During Clinical Use of the Anti-Epileptic Drugs Carbamazepine and Phenytoin

Unraveling the genetic basis of epilepsy: Recent advances and implications for diagnosis and treatment

New anti-epileptic drugs

Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options

Pharmacogenetic and Case-Control Study on Potassium Channel Related Gene Variants and Genetic Generalized Epilepsy